PL3362445T3 - Związki będące pochodnymi oksadiazoloamin jako inhibitor deacetylazy histonowej 6 oraz kompozycja farmaceutyczna obejmujące takie związki - Google Patents
Związki będące pochodnymi oksadiazoloamin jako inhibitor deacetylazy histonowej 6 oraz kompozycja farmaceutyczna obejmujące takie związkiInfo
- Publication number
- PL3362445T3 PL3362445T3 PL16855690.0T PL16855690T PL3362445T3 PL 3362445 T3 PL3362445 T3 PL 3362445T3 PL 16855690 T PL16855690 T PL 16855690T PL 3362445 T3 PL3362445 T3 PL 3362445T3
- Authority
- PL
- Poland
- Prior art keywords
- inhibitor
- pharmaceutical composition
- same
- histone deacetylase
- amine derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150142014 | 2015-10-12 | ||
PCT/KR2016/011355 WO2017065473A1 (en) | 2015-10-12 | 2016-10-11 | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3362445T3 true PL3362445T3 (pl) | 2023-08-07 |
Family
ID=58517488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16855690.0T PL3362445T3 (pl) | 2015-10-12 | 2016-10-11 | Związki będące pochodnymi oksadiazoloamin jako inhibitor deacetylazy histonowej 6 oraz kompozycja farmaceutyczna obejmujące takie związki |
Country Status (21)
Country | Link |
---|---|
US (1) | US10494355B2 (pl) |
EP (1) | EP3362445B1 (pl) |
JP (1) | JP6697074B2 (pl) |
KR (1) | KR101839137B1 (pl) |
CN (1) | CN108699048B (pl) |
AU (1) | AU2016338118B2 (pl) |
CA (1) | CA3001666C (pl) |
DK (1) | DK3362445T3 (pl) |
ES (1) | ES2940413T3 (pl) |
FI (1) | FI3362445T3 (pl) |
HR (1) | HRP20230201T1 (pl) |
HU (1) | HUE061967T2 (pl) |
MX (1) | MX2018004447A (pl) |
MY (1) | MY196174A (pl) |
NZ (1) | NZ740809A (pl) |
PH (1) | PH12018500773A1 (pl) |
PL (1) | PL3362445T3 (pl) |
PT (1) | PT3362445T (pl) |
RU (1) | RU2695133C1 (pl) |
TW (1) | TWI694073B (pl) |
WO (1) | WO2017065473A1 (pl) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY191591A (en) | 2015-02-02 | 2022-06-30 | Forma Therapeutics Inc | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
US10183934B2 (en) | 2015-02-02 | 2019-01-22 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors |
PL3330259T3 (pl) | 2015-07-27 | 2021-02-08 | Chong Kun Dang Pharmaceutical Corp. | Związek pochodna amidowa 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i kompozycja farmaceutyczna go zawierająca |
CA2993929C (en) | 2015-07-27 | 2020-10-20 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
AU2016299486B2 (en) | 2015-07-27 | 2019-08-01 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
HRP20220003T1 (hr) | 2015-08-04 | 2022-04-01 | Chong Kun Dang Pharmaceutical Corp. | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
DK3362445T3 (da) | 2015-10-12 | 2023-02-27 | Chong Kun Dang Pharmaceutical Corp | Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed |
US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
KR102316234B1 (ko) * | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
CA3124324A1 (en) | 2018-12-21 | 2020-06-25 | Bayer Aktiengesellschaft | 1,3,4-oxadiazoles and their derivatives as new antifungal agents |
JP7470058B2 (ja) | 2019-01-30 | 2024-04-17 | 武田薬品工業株式会社 | 複素環化合物 |
CN111848423B (zh) * | 2019-04-30 | 2022-10-14 | 尚科生物医药(上海)有限公司 | 3-氧代环丁基氨基甲酸叔丁酯的制备方法 |
US11453661B2 (en) * | 2019-09-27 | 2022-09-27 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
JP2023508907A (ja) * | 2019-12-20 | 2023-03-06 | テナヤ セラピューティクス, インコーポレイテッド | フルオロアルキル-オキサジアゾールおよびその使用 |
WO2021133957A1 (en) * | 2019-12-27 | 2021-07-01 | Onkure, Inc. | Benzimidazole compounds as hdac6 inhibitors |
BR112022025692A2 (pt) | 2020-06-19 | 2023-02-28 | Bayer Ag | 1,3,4-oxadiazóis e seus derivados como fungicidas |
WO2021255093A1 (en) | 2020-06-19 | 2021-12-23 | Bayer Aktiengesellschaft | Active compound combination |
UY39275A (es) | 2020-06-19 | 2022-01-31 | Bayer Ag | 1,3,4-oxadiazol pirimidinas como fungicidas, procesos e intermediarios para su preparación, métodos de uso y usos de los mismos |
BR112022025710A2 (pt) | 2020-06-19 | 2023-03-07 | Bayer Ag | 1,3,4-oxadiazol pirimidinas e 1,3,4-oxadiazol piridinas como fungicidas |
UY39276A (es) | 2020-06-19 | 2022-01-31 | Bayer Ag | Uso de compuestos de 1,3,4–oxadiazol–2–ilpirimidina para controlar microorganismos fitopatógenos, métodos de uso y composiciones. |
AU2021322052A1 (en) | 2020-08-07 | 2023-03-09 | Italfarmaco S.P.A. | 2-(4-((5-(benzo[b]thiophen-3-yl)-1H-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC6) for use in treating e.g. peripheral neuropathy |
EP4308097A1 (en) * | 2021-03-15 | 2024-01-24 | The Regents Of The University Of Michigan | Non-hydroxamate hdac6 inhibitors and related methods of use |
AU2022262655A1 (en) | 2021-04-23 | 2023-11-02 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
KR20240016950A (ko) | 2021-05-04 | 2024-02-06 | 테나야 테라퓨틱스, 인코포레이티드 | 대사 질환 및 hfpef의 치료에 사용하기 위한 2-플루오로알킬-1,3,4-옥사디아졸-5-일-티아졸, hdac6 억제제 |
IL308122A (en) | 2021-06-16 | 2023-12-01 | Celgene Corp | Azetidinyl compounds consisting of a carboxylic acid group for the treatment of neurodegenerative diseases |
CN115572244A (zh) * | 2021-06-21 | 2023-01-06 | 复旦大学 | 2’-芳基查尔酮类化合物及其制备方法和在制药中的用途 |
US20230322747A1 (en) * | 2022-04-08 | 2023-10-12 | Eikonizo Therapeutics, Inc. | Oxadiazole hdac6 inhibitors and uses thereof |
WO2024033293A1 (en) * | 2022-08-08 | 2024-02-15 | Italfarmaco S.P.A. | Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors |
CN115286615A (zh) * | 2022-09-01 | 2022-11-04 | 深圳市真味生物科技有限公司 | 一种消旋尼古丁的制备方法 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0276432A3 (de) | 1986-12-12 | 1988-10-26 | Ciba-Geigy Ag | Schädlingsbekämpfungsmittel |
KR100265385B1 (ko) | 1998-02-27 | 2000-11-01 | 윤여표 | 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물 |
US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
CA2462601A1 (en) | 2001-10-03 | 2003-04-10 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
MXPA04005927A (es) | 2001-12-20 | 2004-11-01 | Squibb Bristol Myers Co | Derivados de alfa-(n-sulfonamido)acetamida como inhibidores del peptido beta-amiloideo. |
JP2009501236A (ja) | 2005-07-14 | 2009-01-15 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
AU2006278396A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
WO2007032445A1 (ja) | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
MX2008011857A (es) | 2006-03-23 | 2008-12-15 | Prolysis Ltd | Agentes antibacterianos. |
WO2007143822A1 (en) | 2006-06-14 | 2007-12-21 | Methylgene Inc. | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
BRPI0717688A2 (pt) | 2006-12-11 | 2013-01-22 | Genentch Inc Empresa Americana | mÉtodos para tratar neoplasma e mÉtodos para tratar neoplasma de plasmàcitos |
ES2395581T3 (es) | 2007-06-20 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibidores de quinasas janus |
WO2009010479A2 (en) | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | Heterocyclic methylene piperidine derivatives and their use |
KR100903743B1 (ko) | 2007-08-28 | 2009-06-19 | 전병태 | 소화기계 질환개선 및 예방용 식품 조성물 |
WO2009032861A1 (en) | 2007-09-04 | 2009-03-12 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
CN101842392B (zh) | 2007-11-02 | 2014-08-27 | 动量制药公司 | 非抗凝血剂的多糖组合物 |
JP2011502133A (ja) | 2007-11-02 | 2011-01-20 | メシルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
RU2515611C2 (ru) | 2008-07-23 | 2014-05-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Ингибиторы деацетилазы и их применение |
US20120136003A1 (en) | 2009-04-20 | 2012-05-31 | Institute For Oneworld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
JP2011008205A (ja) | 2009-05-27 | 2011-01-13 | Fujifilm Corp | 二軸性光学異方性膜を作製するための組成物 |
CN103221047B (zh) | 2010-01-13 | 2014-12-17 | 坦颇罗制药股份有限公司 | 化合物和方法 |
WO2011088192A1 (en) | 2010-01-13 | 2011-07-21 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
TW201141854A (en) | 2010-02-25 | 2011-12-01 | Piramal Lifesciences Ltd | Oxadiazole compounds, their preparation and use |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
DK2673285T3 (en) | 2010-12-09 | 2017-10-16 | Wockhardt Ltd | Ketolide compounds |
KR101262870B1 (ko) | 2011-01-28 | 2013-05-09 | 환인제약 주식회사 | 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물 |
BR112014000371A2 (pt) | 2011-07-08 | 2017-01-10 | Novartis Ag | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença |
JP6169076B2 (ja) | 2011-07-20 | 2017-07-26 | ザ ジェネラル ホスピタル コーポレイション | 骨疾患の処置のためのヒストン脱アセチル化酵素6選択的阻害剤 |
WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
KR20140097459A (ko) | 2011-11-28 | 2014-08-06 | 노파르티스 아게 | 신규 트리플루오로메틸-옥사디아졸 유도체 및 질환의 치료에서의 그의 용도 |
EP2785720B1 (en) | 2011-11-29 | 2017-08-09 | Nanjing Allgen Pharma Co. Ltd. | Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
EP3041828B1 (en) | 2013-09-06 | 2018-05-23 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
EP3080125B1 (en) | 2013-12-12 | 2018-10-10 | Chong Kun Dang Pharmaceutical Corp. | Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same |
CN104744446B (zh) * | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
CN107108593B (zh) | 2014-11-24 | 2020-03-24 | 美迪福伦Dbt有限公司 | 作为类香草素受体配体ii的基于取代的恶唑和噻唑的羧酰胺和脲衍生物 |
CN106349451B (zh) | 2015-07-14 | 2020-11-13 | 罗门哈斯公司 | 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法 |
PL3330259T3 (pl) | 2015-07-27 | 2021-02-08 | Chong Kun Dang Pharmaceutical Corp. | Związek pochodna amidowa 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i kompozycja farmaceutyczna go zawierająca |
AU2016299486B2 (en) | 2015-07-27 | 2019-08-01 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
CA2993929C (en) | 2015-07-27 | 2020-10-20 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
HRP20220003T1 (hr) * | 2015-08-04 | 2022-04-01 | Chong Kun Dang Pharmaceutical Corp. | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
DK3362445T3 (da) | 2015-10-12 | 2023-02-27 | Chong Kun Dang Pharmaceutical Corp | Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed |
-
2016
- 2016-10-11 DK DK16855690.0T patent/DK3362445T3/da active
- 2016-10-11 MX MX2018004447A patent/MX2018004447A/es unknown
- 2016-10-11 CA CA3001666A patent/CA3001666C/en active Active
- 2016-10-11 HR HRP20230201TT patent/HRP20230201T1/hr unknown
- 2016-10-11 JP JP2018518487A patent/JP6697074B2/ja active Active
- 2016-10-11 ES ES16855690T patent/ES2940413T3/es active Active
- 2016-10-11 MY MYPI2018701042A patent/MY196174A/en unknown
- 2016-10-11 PL PL16855690.0T patent/PL3362445T3/pl unknown
- 2016-10-11 EP EP16855690.0A patent/EP3362445B1/en active Active
- 2016-10-11 AU AU2016338118A patent/AU2016338118B2/en active Active
- 2016-10-11 WO PCT/KR2016/011355 patent/WO2017065473A1/en active Application Filing
- 2016-10-11 NZ NZ740809A patent/NZ740809A/en unknown
- 2016-10-11 RU RU2018117502A patent/RU2695133C1/ru active
- 2016-10-11 US US15/763,972 patent/US10494355B2/en active Active
- 2016-10-11 FI FIEP16855690.0T patent/FI3362445T3/fi active
- 2016-10-11 PT PT168556900T patent/PT3362445T/pt unknown
- 2016-10-11 HU HUE16855690A patent/HUE061967T2/hu unknown
- 2016-10-11 KR KR1020160131245A patent/KR101839137B1/ko active IP Right Grant
- 2016-10-11 CN CN201680072029.8A patent/CN108699048B/zh active Active
- 2016-10-12 TW TW105132939A patent/TWI694073B/zh active
-
2018
- 2018-04-10 PH PH12018500773A patent/PH12018500773A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2940413T3 (es) | 2023-05-08 |
BR112018007289A2 (pt) | 2018-10-23 |
EP3362445A1 (en) | 2018-08-22 |
CA3001666C (en) | 2021-03-30 |
EP3362445B1 (en) | 2023-01-25 |
PH12018500773B1 (en) | 2018-10-29 |
HUE061967T2 (hu) | 2023-09-28 |
CA3001666A1 (en) | 2017-04-20 |
PT3362445T (pt) | 2023-03-20 |
JP6697074B2 (ja) | 2020-05-20 |
PH12018500773A1 (en) | 2018-10-29 |
WO2017065473A1 (en) | 2017-04-20 |
AU2016338118A1 (en) | 2018-04-12 |
EP3362445A4 (en) | 2019-05-22 |
US10494355B2 (en) | 2019-12-03 |
AU2016338118B2 (en) | 2019-03-14 |
KR20170043091A (ko) | 2017-04-20 |
RU2695133C1 (ru) | 2019-07-22 |
TWI694073B (zh) | 2020-05-21 |
MY196174A (en) | 2023-03-20 |
HRP20230201T1 (hr) | 2023-03-31 |
MX2018004447A (es) | 2018-08-01 |
KR101839137B1 (ko) | 2018-03-26 |
FI3362445T3 (fi) | 2023-03-21 |
NZ740809A (en) | 2019-04-26 |
US20180273495A1 (en) | 2018-09-27 |
DK3362445T3 (da) | 2023-02-27 |
CN108699048B (zh) | 2021-12-28 |
TW201716397A (zh) | 2017-05-16 |
JP2018530571A (ja) | 2018-10-18 |
CN108699048A (zh) | 2018-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1254756A1 (zh) | 作為組蛋白脫乙酰酶6抑制劑的1,3,4-噁二唑衍生物化合物及包含其的藥物組合物 | |
PL3362445T3 (pl) | Związki będące pochodnymi oksadiazoloamin jako inhibitor deacetylazy histonowej 6 oraz kompozycja farmaceutyczna obejmujące takie związki | |
HK1251571A1 (zh) | 作為組蛋白脫乙酰基酶6抑制劑的1,3,4-噁二唑磺酰胺衍生化合物及含有其的醫藥組合物 | |
HK1251549A1 (zh) | 作為組蛋白去乙酰酶6抑制劑的1,3,4-噁二唑磺酰胺衍生物及含其的醫藥組合物 | |
HK1251939A1 (zh) | 作為組蛋白脫乙酰酶6抑制劑的1,3,4-噁二唑酰胺衍生物化合物及含有其的藥物組合物 | |
HRP20181534T1 (hr) | Novi spojevi kao inhibitori histonske deacetilaze 6 i farmaceutski pripravci koji ih sadrže | |
IL263082B (en) | New compounds as ototaxin inhibitors and pharmaceutical preparations containing them | |
IL252828A0 (en) | Piperidine derivative compounds suppressing hdac1/2 preparations containing them and their uses | |
IL274973A (en) | History of 4,2,1-oxadiazole as histone deacetylase inhibitors | |
HK1251556A1 (zh) | 用作選擇性組蛋白脫乙酰酶抑制劑的雜環烷基衍生化合物及含其的藥物組合物 | |
PT3827004T (pt) | Derivados da 4-(1,3,4-oxadiazol-2-il)piridin-2(1h)-ona como inibidores da histona desacetilase 6 (hdac6) para o tratamento de infeções e.g. | |
IL264765B2 (en) | Amide compounds, their pharmaceutical preparations and methods of using them |